Results 21 to 30 of about 656,371 (370)

Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma

Journal of Hematology & Oncology, 2021
The assessment of measurable residual disease (MRD) in bone marrow has proven of prognostic relevance in patients with multiple myeloma (MM). Nevertheless, and unlike other hematologic malignancies, the use of MRD results to make clinical decisions in MM
Joaquin Martinez-Lopez, Rafael Alonso, Sandy W. Wong, Rafael Rios, Nina Shah, Yanira Ruiz-Heredia, Jose Maria Sanchez-Pina, Ricardo Sanchez, Natasha Bahri, Irene Zamanillo, Maria Poza, Natalia Buenache, Cristina Encinas, Luis Juarez, Fatima Miras, Luis Collado, Santiago Barrio, Thomas Martin, Maria Teresa Cedena, Jeffrey Wolf   +19 more
doaj   +1 more source

The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies

Cancers, 2022
Simple Summary Monitoring the response to treatment in hematologic malignancies is essential in defining the best way to optimize patient management. In general, achieving a deeper response has been shown to lead to a better prognosis, and the techniques
R. Colmenares, N. Alvarez, S. Barrio, J. Martínez-López, R. Ayala   +4 more
semanticscholar   +1 more source

RCA-IUnet: A residual cross-spatial attention guided inception U-Net model for tumor segmentation in breast ultrasound imaging [PDF]

Machine Vision and Applications, Springer, 2022, 2021
The advancements in deep learning technologies have produced immense contributions to biomedical image analysis applications. With breast cancer being the common deadliest disease among women, early detection is the key means to improve survivability. Medical imaging like ultrasound presents an excellent visual representation of the functioning of the ...
arxiv   +1 more source

Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

BMC Cancer, 2022
Background Multiple myeloma remains an incurable disease with multiple relapses due to residual myeloma cells in the bone marrow of patients after therapy.
Alexander Schmitz, Rasmus Froberg Brøndum, Hans Erik Johnsen, Ulf-Henrik Mellqvist, Anders Waage, Peter Gimsing, Davine Hofste op Bruinink, Vincent van der Velden, Bronno van der Holt, Markus Hansson, Niels Frost Andersen, Ulf Christian Frølund, Carsten Helleberg, Fredrik H. Schjesvold, Lucia Ahlberg, Nina Gulbrandsen, Bjorn Andreasson, Birgitta Lauri, Einar Haukas, Julie Støve Bødker, Anne Stidsholt Roug, Martin Bøgsted, Marianne T. Severinsen, Henrik Gregersen, Niels Abildgaard, Pieter Sonneveld, Karen Dybkær   +26 more
doaj   +1 more source

Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy.

Blood Cancer Discovery, 2021
We evaluate clinical significance of recently identified subtypes of acute lymphoblastic leukemia (ALL) in 598 children treated with minimal residual disease (MRD)-directed therapy.
S. Jeha, J. Choi, K. Roberts, Deqing Pei, E. Coustan-Smith, H. Inaba, J. Rubnitz, R. Ribeiro, T. Gruber, S. Raimondi, Seth E. Karol, Chunxu Qu, Samuel W. Brady, Zhaohui Gu, Jun J. Yang, Cheng Cheng, J. Downing, W. Evans, M. Relling, D. Campana, C. Mullighan, C. Pui   +21 more
semanticscholar   +1 more source

Drug resistance and minimal residual disease in multiple myeloma [PDF]

, 2022
Great progress has been made in improving survival in multiple myeloma (MM) patients over the last 30 years. New drugs have been introduced and complete responses are frequently seen.
Bocchia M., Cencini E., Ciofini S., Gozzetti A., Pacelli P., Raspadori D., Sicuranza A., Tocci D.   +7 more
core   +1 more source

Sustained Minimal Residual Disease Negativity With Daratumumab in Newly Diagnosed Multiple Myeloma: MAIA and ALCYONE.

Blood, 2021
In patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab reduced the risk of disease progression or death by 44% in MAIA (daratumumab/lenalidomide/dexamethasone; D-Rd) and 58% in ALCYONE (daratumumab/bortezomib ...
San Miguel Jesus, H. Avet-Loiseau, B. Paiva, Shaji K. Kumar, M. Dimopoulos, T. Facon, M. Mateos, C. Touzeau, A. Jakubowiak, S. Usmani, G. Cook, M. Cavo, H. Quach, J. Ukropec, P. Ramaswami, H. Pei, M. Qi, Steven Sun, Jianping Wang, M. Krevvata, Nikki A. Deangelis, C. Heuck, Rian Van Rampelbergh, Anupa Kudva, R. Kobos, M. Qi, N. Bahlis   +26 more
semanticscholar   +1 more source

Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives

Frontiers in Oncology, 2021
Circulating tumor DNA (ctDNA) is cell-free DNA (cfDNA) fragment in the bloodstream that originates from malignant tumors or circulating tumor cells. Recently, ctDNA has emerged as a promising non-invasive biomarker in clinical oncology. Analysis of ctDNA
Yan Peng, W. Mei, Kaidong Ma, Changchun Zeng   +3 more
semanticscholar   +1 more source

Case report: Real-world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenarios

Frontiers in Oncology, 2022
Circulating-tumor DNA (ctDNA) has emerged as an important biomarker for monitoring disease status in cancer patients. Different ctDNA testing platforms have shown promising results in the early detection of disease, monitoring response to treatment, and ...
Karam Khaddour, Karam Khaddour, Alice Zhou, Omar H. Butt, Griffin Budde, Allyson Koyen Malashevich, George Ansstas   +6 more
doaj   +1 more source

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA.

Blood, 2021
We explored minimal residual disease (MRD) in relapsed/refractory multiple myeloma (RRMM) and transplant-ineligible newly diagnosed multiple myeloma (TIE NDMM) using data from four phase 3 studies (POLLUX, CASTOR, ALCYONE, and MAIA).
M. Cavo, J. San-Miguel, S. Usmani, K. Weisel, M. Dimopoulos, H. Avet-Loiseau, B. Paiva, N. Bahlis, T. Plesner, V. Hungria, P. Moreau, M. Mateos, A. Perrot, S. Iida, T. Facon, Shaji K. Kumar, N. V. D. van de Donk, P. Sonneveld, A. Spencer, M. Krevvata, C. Heuck, Jianping Wang, J. Ukropec, R. Kobos, Steven Sun, M. Qi, N. Munshi   +26 more
semanticscholar   +1 more source